<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35395837</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2057-4967</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>08</Day>
            </PubDate>
          </JournalIssue>
          <Title>Chinese neurosurgical journal</Title>
          <ISOAbbreviation>Chin Neurosurg J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>9</StartPage>
          <MedlinePgn>9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">9</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s41016-022-00277-1</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">For prolactinoma patients, dopamine agonists (DAs) are indicated as the first-line treatment and surgery is an adjunctive choice. However, with the development of surgical technique and equipment, the effect of surgery has improved. The aim of this study was to assess the efficacy and safety of surgery versus DAs in patients with different types of prolactinomas.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A systematic search of literature using Web of Science, PubMed, Cochrane Library, and Clinical Trial databases was conducted until July 12, 2019. Prolactinoma patients treated with DAs (bromocriptine or cabergoline) or surgery (microscopic or endoscopic surgery) were included. Outcomes included the biochemical cure rate, recurrence rate, prolactin level, improvement rates of symptoms, and incidence rates of complications. A random-effects model was used to pool the extracted data. Qualitative comparisons were conducted instead of quantitative comparison.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">DAs were better than surgery in terms of the biochemical cure rate (0.78 versus 0.66), but surgery had a much lower recurrence rate (0.19 versus 0.57). Full advantages were not demonstrated in improvement rates of symptoms and incidence rates of complications with both treatment options. In microprolactinoma patients, the biochemical cure rate of endoscopic surgery was equal to the average cure rate of DAs (0.86 versus 0.86) and it surpassed the biochemical cure rate of bromocriptine (0.86 versus 0.76). In macroprolactinoma patients, endoscopic surgery was slightly higher than bromocriptine (0.66 versus 0.64) in terms of the biochemical cure rate.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">For patients with clear indications or contraindications for surgery, choosing surgery or DAs accordingly is unequivocal. However, for patients with clinical equipoise, such as surgery, especially endoscopic surgery, in microprolactinoma and macroprolactinoma patients, we suggest that neurosurgeons and endocrinologists conduct high-quality clinical trials to address the clinical equipoise quantitatively.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Xiangming</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Southeast University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Junhao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Jin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Chao</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Jinling Hospital, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cong</LastName>
            <ForeName>Zixiang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Jinling Hospital, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Chiyuan</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-1710-5955</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Southeast University, Nanjing, China. machiyuan_nju@126.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Nanjing Medical University, Nanjing, China. machiyuan_nju@126.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Jinling Hospital, Nanjing, China. machiyuan_nju@126.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Nanjing University, Nanjing, China. machiyuan_nju@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Chin Neurosurg J</MedlineTA>
        <NlmUniqueID>101672561</NlmUniqueID>
        <ISSNLinking>2057-4967</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Bromocriptine</Keyword>
        <Keyword MajorTopicYN="N">Cabergoline</Keyword>
        <Keyword MajorTopicYN="N">Dopamine agonists</Keyword>
        <Keyword MajorTopicYN="N">Endoscopic surgery</Keyword>
        <Keyword MajorTopicYN="N">Microscopic surgery</Keyword>
        <Keyword MajorTopicYN="N">Prolactinoma</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>5</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35395837</ArticleId>
        <ArticleId IdType="pmc">PMC8994364</ArticleId>
        <ArticleId IdType="doi">10.1186/s41016-022-00277-1</ArticleId>
        <ArticleId IdType="pii">10.1186/s41016-022-00277-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wong A, Eloy JA, Couldwell WT, Liu JK. Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges. J Clin Neurosci. 2015;22:1562–1567. doi: 10.1016/j.jocn.2015.03.058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2015.03.058</ArticleId>
            <ArticleId IdType="pubmed">26256063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faje A, Nachtigall L. Current treatment options for hyperprolactinemia. Expert Opin Pharmacother. 2013;14:1611–1625. doi: 10.1517/14656566.2013.806488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14656566.2013.806488</ArticleId>
            <ArticleId IdType="pubmed">23738973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berezin M, Shimon I, Hadani M. Prolactinoma in 53 men: Clinical characteristics and modes of treatment (male prolactinoma) J Endocrinol Invest. 1995;18:436–441. doi: 10.1007/BF03349742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF03349742</ArticleId>
            <ArticleId IdType="pubmed">7594238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samaan NA, Schultz PN, Leavens TA, Leavens ME, Lee YY. Pregnancy after treatment in patients with prolactinoma: Operation versus bromocriptine. Am J Obstet Gynecol. 1986;155:1300–1305. doi: 10.1016/0002-9378(86)90164-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0002-9378(86)90164-X</ArticleId>
            <ArticleId IdType="pubmed">3789042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamidi O, Van Gompel J, Gruber L, Kittah NE, Donegan D, Philbrick KA, et al.  Management and outcomes of giant prolactinoma: a series of 71 patients. Endocr Pract. 2019;25:340–352. doi: 10.4158/EP-2018-0392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4158/EP-2018-0392</ArticleId>
            <ArticleId IdType="pubmed">30995432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong JW, Lee MK, Kim SH, Lee EJ. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma. Endocrine. 2010;37:140–147. doi: 10.1007/s12020-009-9279-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-009-9279-7</ArticleId>
            <ArticleId IdType="pubmed">20963563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asano S, Ueki K, Suzuki I, Kirino T. Clinical features and medical treatment of male prolactinomas. Acta Neurochir (Wien). 2001;143:465–470. doi: 10.1007/s007010170075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s007010170075</ArticleId>
            <ArticleId IdType="pubmed">11482696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andereggen L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW, et al.  10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine. 2017;55:223–230. doi: 10.1007/s12020-016-1115-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-016-1115-2</ArticleId>
            <ArticleId IdType="pubmed">27688009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker-van Marle ME, Pereira AM, et al. Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020;105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7112976</ArticleId>
            <ArticleId IdType="pubmed">31665485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Q, Su J, Li Y, Wang J, Long W, Luo M, et al.  The chance of permanent cure for micro- and macroprolactinomas, medication or surgery? A systematic review and meta-analysis. Front Endocrinol. 2018;9:1–10. doi: 10.3389/fendo.2018.00001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2018.00001</ArticleId>
            <ArticleId IdType="pmc">PMC6209637</ArticleId>
            <ArticleId IdType="pubmed">30410470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamba N, Noormohamed N, Simjian T, Alsheikhb MY, Jamalb A, Doucetteb J, et al.  Fertility after transsphenoidal surgery in patients with prolactinomas: A meta-analysis. Clin Neurol Neurosurg. 2019;176:53–60. doi: 10.1016/j.clineuro.2018.11.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clineuro.2018.11.024</ArticleId>
            <ArticleId IdType="pubmed">30529652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hutton B, Wolfe D, Moher D, Shamseer L. Reporting guidance considerations from a statistical perspective: overview of tools to enhance the rigour of reporting of randomised trials and systematic reviews. Evid Based Ment Health. 2017;20:46–52. doi: 10.1136/eb-2017-102666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/eb-2017-102666</ArticleId>
            <ArticleId IdType="pubmed">28363989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv L, Hu Y, Yin S, Zhou P, Yang Y, Ma W, et al.  Giant prolactinomas: Outcomes of multimodal treatments for 42 cases with long-term follow-up. Exp Clin Endocrinol Diabetes. 2019;127:295. doi: 10.1055/a-0597-8877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/a-0597-8877</ArticleId>
            <ArticleId IdType="pubmed">29940665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi: 10.1136/bmj.i4919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.i4919</ArticleId>
            <ArticleId IdType="pmc">PMC5062054</ArticleId>
            <ArticleId IdType="pubmed">27733354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId>
            <ArticleId IdType="pubmed">31462531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo B, Moga C, Harstall C, Schopflocher D. A principal component analysis is conducted for a case series quality appraisal checklist. J Clin Epidemiol. 2016;69(199-207):e2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26307459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zarate A, Canales ES, Alger M, Forsbach G. The effect of pregnancy and lactation on pituitary prolactin-secreting tumours. Acta Endocrinol (Copenh). 1979;92:407–412. doi: 10.1530/acta.0.0920407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/acta.0.0920407</ArticleId>
            <ArticleId IdType="pubmed">517046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coculescu M, Simionescu N, Oprescu M, D. A. Bromocriptine treatment of pituitary adenomas. Evaluation of withdrawal effect. Endocrinologie. 1983;21:157–168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6635518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nissim M, Ambrosi B, Bernasconi V, Giannattasio G, Giovanelli MA, Bassetti M, et al.  Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology. J Endocrinol Invest. 1982;5:409–415. doi: 10.1007/BF03350542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF03350542</ArticleId>
            <ArticleId IdType="pubmed">7169515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Archer DF, Lattanzi DR, Moore EE, Harger JH, Herbert DL. Bromocriptine treatment of women with suspected pituitary prolactin-secreting microadenomas. Am J Obstet Gynecol. 1982;143:620. doi: 10.1016/0002-9378(82)90106-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0002-9378(82)90106-5</ArticleId>
            <ArticleId IdType="pubmed">7201244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hancock KW, Scott JS, Lamb JT, Gibson RM, Chapman C. Conservative management of pituitary prolactinomas ; evldence for bromocriptine-induced regression. Br J Obstet Gynaecol. 1980;87:523–529. doi: 10.1111/j.1471-0528.1980.tb04590.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-0528.1980.tb04590.x</ArticleId>
            <ArticleId IdType="pubmed">7397087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hildebrandt G, Bauer T, Stracke H, Fassbender WJ, Mueller HW, Agnoli AL, et al.  Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up. Zentralbl Neurochir. 1992;53:123–134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1414079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beckers A, Petrossians P, Abs R, Flandroy P, Stadnik T, De Longueville M, et al.  Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases. J Clin Endocrinol Metab. 1992;75:275–280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1619019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van T, Verlaat JW, Croughs RJ. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf). 1991;34:175–178. doi: 10.1111/j.1365-2265.1991.tb00289.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.1991.tb00289.x</ArticleId>
            <ArticleId IdType="pubmed">2036725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verlaat JWV, Croughs RJM, Hendriks MJ, Bosma NJ. Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension. Can J Neurol Sci. 1990;17:71–73. doi: 10.1017/S0317167100030079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S0317167100030079</ArticleId>
            <ArticleId IdType="pubmed">2311021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hildebrandt G, Zierski J, Christophis P, Laun A, Schatz H, Lancranjan I, et al.  Rhinorrhea following dopamine agonist therapy of invasive macroprolaetinoma. Acta Neurochir (Wien). 1989;96:107–113. doi: 10.1007/BF01456167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01456167</ArticleId>
            <ArticleId IdType="pubmed">2711893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, Lam KSL, Ma JTC, Chan T, Liu MY, Yeung RTT. Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol (Oxf). 1987;27:363–371. doi: 10.1111/j.1365-2265.1987.tb01163.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.1987.tb01163.x</ArticleId>
            <ArticleId IdType="pubmed">3427794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D'Alberton A, Crosignani P. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh). 1992;126:489–494. doi: 10.1530/acta.0.1260489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/acta.0.1260489</ArticleId>
            <ArticleId IdType="pubmed">1642081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarno AD, Landi ML, Cappabianca P, Salle FD, Rossi FW, Pivonello R, et al.  Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: Prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001;86:5256–5261. doi: 10.1210/jcem.86.11.8054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.86.11.8054</ArticleId>
            <ArticleId IdType="pubmed">11701688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, et al.  Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients. J Clin Endocrinol Metab. 2000;85:2247–2252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10852458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cannavò S, Curtò L, Squadrito S, Almoto B, Vieni A, Trimarchi F. Cabergoline: A first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest. 1999;22:354–359. doi: 10.1007/BF03343573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF03343573</ArticleId>
            <ArticleId IdType="pubmed">10401709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, et al.  Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82:876–883. doi: 10.1210/jcem.82.3.3822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.82.3.3822</ArticleId>
            <ArticleId IdType="pubmed">9062500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrari CI, Abs R, Bevan JS, Barbant G, Ciccarelli E, Motta T, et al.  Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf). 1997;46:409–413. doi: 10.1046/j.1365-2265.1997.1300952.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2265.1997.1300952.x</ArticleId>
            <ArticleId IdType="pubmed">9196602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest. 1997;20:537–546. doi: 10.1007/BF03348016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF03348016</ArticleId>
            <ArticleId IdType="pubmed">9413808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delgrange EDM, Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol. 1996;134:454–456. doi: 10.1530/eje.0.1340454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/eje.0.1340454</ArticleId>
            <ArticleId IdType="pubmed">8640297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabuncu T, Arikan E, Tasan E, Hatemi H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern Med. 2001;40:857–861. doi: 10.2169/internalmedicine.40.857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.40.857</ArticleId>
            <ArticleId IdType="pubmed">11579944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naliato ECO, Violante AHD, Caldas D, Filho AL, Loureiro CR, Fontes R, et al.  Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol (Oxf). 2007;67:845–852. doi: 10.1111/j.1365-2265.2007.02973.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.2007.02973.x</ArticleId>
            <ArticleId IdType="pubmed">17645576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol. 2007;156:225–231. doi: 10.1530/EJE-06-0646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-06-0646</ArticleId>
            <ArticleId IdType="pubmed">17287412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, et al.  Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf). 2007;67:426–433. doi: 10.1111/j.1365-2265.2007.02905.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.2007.02905.x</ArticleId>
            <ArticleId IdType="pubmed">17573902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chattopadhyay A, Bhansali A, Masoodi SR. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary. 2005;8:147–154. doi: 10.1007/s11102-005-5111-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-005-5111-4</ArticleId>
            <ArticleId IdType="pubmed">16379032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, et al.  Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf). 2005;63:26–31. doi: 10.1111/j.1365-2265.2005.02293.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.2005.02293.x</ArticleId>
            <ArticleId IdType="pubmed">15963057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colao A, Vitale G, Di Sarno A, Spiezia S, Guerra E, Ciccarelli A, et al.  Prolactin and prostate hypertrophy: A pilot observational, prospective, case-control study in men with prolactinoma. J Clin Endocrinol Metab. 2004;89:2770–2775. doi: 10.1210/jc.2003-032055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2003-032055</ArticleId>
            <ArticleId IdType="pubmed">15181056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, et al.  Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf). 2003;58:662–670. doi: 10.1046/j.1365-2265.2003.01770.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2265.2003.01770.x</ArticleId>
            <ArticleId IdType="pubmed">12699451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Essas O, Bouguerra R, Hamzaoui J, Marrakchi Z, Hadjri S, Chamakhi S, et al.  Efficacy and safety of bromocriptine in the treatment of macroprolactinomas. Annales d'Endocrinologie. 2002;63:524–531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12527854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dos Santos Silva CM, Barbosa FRP, Lima GAB, Warszawski L, Fontes R, Domingues RC, et al.  BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity. 2010;19:800–805. doi: 10.1038/oby.2010.150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/oby.2010.150</ArticleId>
            <ArticleId IdType="pubmed">20559294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhansali A, Walia R, Dutta P, Khandelwal N, Sialy R, Bhadada S. Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas. Indian J Med Res. 2010;131:530–535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20424304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huda MSB, Athauda NB, Teh MM, Carroll PV, Powrie JK. Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin Endocrinol (Oxf). 2010;72:507–511. doi: 10.1111/j.1365-2265.2009.03657.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.2009.03657.x</ArticleId>
            <ArticleId IdType="pubmed">19549247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acharya S, Gopal R, Menon P, Bandgar TR, Shah NS. Giant prolactinoma and effectiveness of medical management. Endocr Pract. 2010;16:42–46. doi: 10.4158/EP09221.OR.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4158/EP09221.OR</ArticleId>
            <ArticleId IdType="pubmed">19703803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, et al.  Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. Obstet Gynecol Surv. 2010;65:702–704. doi: 10.1097/OGX.0b013e31820220ab.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/OGX.0b013e31820220ab</ArticleId>
            <ArticleId IdType="pubmed">20357175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009;160:747–752. doi: 10.1530/EJE-09-0012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-09-0012</ArticleId>
            <ArticleId IdType="pubmed">19223454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acharya SV, Gopal RA, Bandgar TR, Joshi SR, Menon PS, Shah NS. Clinical profile and long term follow up of children and adolescents with prolactinomas. Pituitary. 2009;12:186–189. doi: 10.1007/s11102-008-0149-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-008-0149-8</ArticleId>
            <ArticleId IdType="pubmed">18946737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho E, Lee SA, Chung JY, Koh EH, Cho YH, Kim JH, et al.  Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. J Korean Med Sci. 2009;24:874. doi: 10.3346/jkms.2009.24.5.874.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3346/jkms.2009.24.5.874</ArticleId>
            <ArticleId IdType="pmc">PMC2752771</ArticleId>
            <ArticleId IdType="pubmed">19794986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naliato ECDO, Violante AHD, Caldas D, Farias MLF, Bussade I, Filho AL, et al.  Bone density in women with prolactinoma treated with dopamine agonists. Pituitary. 2008;11:21–28. doi: 10.1007/s11102-007-0064-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-007-0064-4</ArticleId>
            <ArticleId IdType="pubmed">17661178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Auriemma RS, Galdiero M, Vitale P, Granieri L, Lo Calzo F, Salzano C, et al.  Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology. 2013;98:299–310. doi: 10.1159/000357810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000357810</ArticleId>
            <ArticleId IdType="pubmed">24355865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol (Oxf). 2013;79:845–852. doi: 10.1111/cen.12204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen.12204</ArticleId>
            <ArticleId IdType="pubmed">23506485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin DSYL, Andia MV, Jara AA. Long-term evolution and outcomes of microprolactinoma with medical treatment. Endocrinol Nutr. 2013;60:489–494. doi: 10.1016/j.endonu.2013.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.endonu.2013.03.007</ArticleId>
            <ArticleId IdType="pubmed">23834767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kallestrup M, Kasch H, Østerby T, Nielsen E, Jensen TS, Jørgensen JOL. Prolactinoma-associated headache and dopamine agonist treatment. Cephalalgia. 2013;34:493–502. doi: 10.1177/0333102413515343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0333102413515343</ArticleId>
            <ArticleId IdType="pubmed">24351278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rastogi A, Walia R, Dutta P, Bhansali A. Efficacy and safety of rapid escalation of cabergoline in comparison to conventional regimen for macroprolactinoma: A prospective, randomized trial. Indian J Endocrinol Metab. 2012;16:S294–S296. doi: 10.4103/2230-8210.104064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/2230-8210.104064</ArticleId>
            <ArticleId IdType="pmc">PMC3603052</ArticleId>
            <ArticleId IdType="pubmed">23565404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anagnostis P, Adamidou F, Polyzos SA, Efstathiadou Z, Karathanassi E, Kita M. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary. 2012;15:25–29. doi: 10.1007/s11102-011-0303-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-011-0303-6</ArticleId>
            <ArticleId IdType="pubmed">21409614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang MS, Hong JW, Lee SK, Lee EJ, Kim SH. Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist. J Neurooncol. 2011;104:195–204. doi: 10.1007/s11060-010-0459-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-010-0459-3</ArticleId>
            <ArticleId IdType="pubmed">21107645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berinder K, Nyström T, Höybye C, Hall K, Hulting A-L. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011;14:199–207. doi: 10.1007/s11102-010-0277-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-010-0277-9</ArticleId>
            <ArticleId IdType="pubmed">21128120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barber TM, Kenkre J, Garnett C, Scott RV, Byrne JV, Wass JAH. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma. Clin Endocrinol (Oxf). 2011;75:819–824. doi: 10.1111/j.1365-2265.2011.04136.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.2011.04136.x</ArticleId>
            <ArticleId IdType="pubmed">21645021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishio H, Fujii T, Kameyama K. Abdominal radical trachelectomy as a fertility-sparing procedure in women with early stage cervical cancer in a series of 61 women. Obstet Gynecol Surv. 2010;65:19–20. doi: 10.1097/OGX.0b013e3181c87c0f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/OGX.0b013e3181c87c0f</ArticleId>
            <ArticleId IdType="pubmed">19646742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aycicek Dogan B, Arduc A, Tuna MM, Nasıroğlu NI, Işık S, Berker D, et al.  Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma. Anatol J Cardiol. 2015;16:440–447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5331378</ArticleId>
            <ArticleId IdType="pubmed">26680550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almalki MH, Buhary B, Alzahrani S, Alshahrani F, Alsherbeni S, Alhowsawi G, et al.  Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases. Pituitary. 2015;18:405–409. doi: 10.1007/s11102-014-0588-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-014-0588-3</ArticleId>
            <ArticleId IdType="pubmed">25062894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pala NA, Laway BA, Misgar RA, Dar RA. Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetology Metab Syndr. 2015;7:1–6. doi: 10.1186/1758-5996-7-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1758-5996-7-1</ArticleId>
            <ArticleId IdType="pmc">PMC4650139</ArticleId>
            <ArticleId IdType="pubmed">26583049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tirosh A, Benbassat C, Shimon I. Short-term decline in prolactin concentrations can predict future prolactin normalization, tumor shrinkage, and time to remission in men with macroprolactinomas. Endocr Pract. 2015;21:1240–1247. doi: 10.4158/EP15804.OR.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4158/EP15804.OR</ArticleId>
            <ArticleId IdType="pubmed">26247115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kruljac I, Kirigin LS, Strinović M, Marinkovic J, PeTina HI, Herina V, et al.  Treatment of prolactinomas in low-income countries. Int J Endocrinol. 2015;0:1–5. doi: 10.1155/2015/697065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2015/697065</ArticleId>
            <ArticleId IdType="pmc">PMC4337182</ArticleId>
            <ArticleId IdType="pubmed">25737721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee Y, Ku CR, Kim E, Hong JW, Lee EJ, Kim SH. Early prediction of long-term response to cabergoline in patients with macroprolactinomas. Endocrinol Metab. 2014;29:280. doi: 10.3803/EnM.2014.29.3.280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3803/EnM.2014.29.3.280</ArticleId>
            <ArticleId IdType="pmc">PMC4192821</ArticleId>
            <ArticleId IdType="pubmed">25309786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbosa FRP, Dos Santos Silva CM, Lima GAB, Warszawski L, Domingues RC, Dominic M, et al.  Prevalence of obstructive sleep apnea in patients with prolactinoma before and after treatment with dopamine agonists. Pituitary. 2014;17:441–449. doi: 10.1007/s11102-013-0524-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-013-0524-y</ArticleId>
            <ArticleId IdType="pubmed">24068456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rastogi A, Bhansali A, Dutta P, Singh P, Vijaivergiya R, Gupta V, et al.  A comparison between intensive and conventional cabergoline treatment of newly diagnosed patients with macroprolactinoma. Clin Endocrinol (Oxf). 2013;79:409–415. doi: 10.1111/cen.12149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen.12149</ArticleId>
            <ArticleId IdType="pubmed">23347435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho KR, Jo K, Shin HJ. Bromocriptine therapy for the treatment of invasive prolactinoma: The single institute experience. Brain Tumor Res Treat. 2013;1:71–77. doi: 10.14791/btrt.2013.1.2.71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14791/btrt.2013.1.2.71</ArticleId>
            <ArticleId IdType="pmc">PMC4027106</ArticleId>
            <ArticleId IdType="pubmed">24904895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karavitaki N, Dobrescu R, Byrne JV, Grossman AB, Wass JAH. Does hypopituitarism recover when macroprolactinomas are treated with cabergoline? Clin Endocrinol (Oxf). 2013;79:217–223. doi: 10.1111/cen.12124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen.12124</ArticleId>
            <ArticleId IdType="pubmed">23215960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araujo B, Belo S, Carvalho D. Pregnancy and tumor outcomes in women with prolactinoma. Exp Clin Endocrinol Diabetes. 2017;125:642. doi: 10.1055/s-0043-112861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0043-112861</ArticleId>
            <ArticleId IdType="pubmed">28704852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teixeira M, Souteiro P, Carvalho D. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal. Pituitary. 2017;20:464–470. doi: 10.1007/s11102-017-0806-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-017-0806-x</ArticleId>
            <ArticleId IdType="pubmed">28523537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santharam S, Tampourlou M, Arlt W, Ayuk J, Gittoes N, Toogood A, et al.  Prolactinomas diagnosed in the postmenopausal period: Clinical phenotype and outcomes. Clin Endocrinol (Oxf). 2017;87:508–514. doi: 10.1111/cen.13399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen.13399</ArticleId>
            <ArticleId IdType="pubmed">28626987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwetz V, Librizzi R, Trummer C, Theiler G, Stiegler C, Pieber TR, et al.  Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas. Metab Brain Dis. 2017;32:155–161. doi: 10.1007/s11011-016-9882-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11011-016-9882-2</ArticleId>
            <ArticleId IdType="pmc">PMC5566581</ArticleId>
            <ArticleId IdType="pubmed">27525431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yedinak CG, Cetas I, Ozpinar A, McCartney S, Dogan A, Fleseriu M. Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience. Endocrine. 2016;54:191–197. doi: 10.1007/s12020-016-1042-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-016-1042-2</ArticleId>
            <ArticleId IdType="pubmed">27460005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimon I, Sosa E, Mendoza V, Greenman Y, Tirosh A, Espinosa E, et al.  Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary. 2016;19:429–436. doi: 10.1007/s11102-016-0723-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-016-0723-4</ArticleId>
            <ArticleId IdType="pubmed">27138902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Espinosa E, Sosa E, Mendoza V, Ramırez C, Melgar V, Mercado MS. Giant prolactinomas: are they really different from ordinary macroprolactinomas? Endocrine. 2016;52:652–659. doi: 10.1007/s12020-015-0791-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-015-0791-7</ArticleId>
            <ArticleId IdType="pubmed">26561015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mallea-Gil MS, Manavela M, Alfieri A, Ballarino MC, Chervin A, Danilowicz K, et al.  Prolactinomas: evolution after menopause. Arch Endocrinol Metab. 2016;60:42–46. doi: 10.1590/2359-3997000000138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/2359-3997000000138</ArticleId>
            <ArticleId IdType="pubmed">26909481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dogansen SC, Selcukbiricik OS, Tanrikulu S, Yarman S. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when? Pituitary. 2016;19:303–310. doi: 10.1007/s11102-016-0708-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-016-0708-3</ArticleId>
            <ArticleId IdType="pubmed">26830552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Auriemma RS, Galdiero M, Vitale P, Granieri L, Calzo FL, Salzano C, et al.  Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology. 2015;191:66–81. doi: 10.1159/000371851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000371851</ArticleId>
            <ArticleId IdType="pubmed">25592453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji MJ, Kim JH, Lee JH, Lee JH, Kim YH, Paek SH, et al.  Best candidates for dopamine agonist withdrawal in patients with prolactinomas. Pituitary. 2017;20:578–584. doi: 10.1007/s11102-017-0820-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-017-0820-z</ArticleId>
            <ArticleId IdType="pubmed">28710724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paepegaey A, Salenave S, Kamenicky P, Maione L, Brailly-Tabard S, Young J, et al.  Cabergoline tapering is almost always successful in patients with macroprolactinomas. J Endocrine Soc. 2017;1:221–230. doi: 10.1210/js.2017-00038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/js.2017-00038</ArticleId>
            <ArticleId IdType="pmc">PMC5686686</ArticleId>
            <ArticleId IdType="pubmed">29264479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akinduro OO, Lu VM, Izzo A, Biase GD, Vilanilam G, Gompel JJV, et al.  Radiographic and hormonal regression in prolactinomas: An analysis of treatment failure. World Neurosurg. 2019;249:e1–e9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31181361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santharam S, Fountas A, Tampourlou M, Arlt W, Ayuk J, Gittoes N, et al.  Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin Endocrinol (Oxf). 2018;89:346–353. doi: 10.1111/cen.13765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen.13765</ArticleId>
            <ArticleId IdType="pubmed">29894000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Celik E, Ozkaya HM, Poyraz BC, Saglam T, Kadioglu P. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. Endocrine. 2018;62:692–700. doi: 10.1007/s12020-018-1744-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-018-1744-8</ArticleId>
            <ArticleId IdType="pubmed">30206771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araújo C, Marques O, Almeida R, Santos MJ. Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses. Endocrine. 2018;62:470–476. doi: 10.1007/s12020-018-1703-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-018-1703-4</ArticleId>
            <ArticleId IdType="pubmed">30088141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dogansen SC, Cikrikcili U, Oruk G, Kutbay NO, Tanrikulu S, Hekimsoy Z, et al.  Dopamine agonist-induced impulse control disorders in patients with prolactinoma: A cross-sectional multicenter study. J Clin Endocrinol Metab. 2019;104:2527–2534. doi: 10.1210/jc.2018-02202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2018-02202</ArticleId>
            <ArticleId IdType="pubmed">30848825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimon I, Hirsch D, Tsvetov G, Robenshtok E, Akirov A, Fraenkel M, et al.  Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years. Endocrine. 2019;65:656–661. doi: 10.1007/s12020-019-01962-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-019-01962-5</ArticleId>
            <ArticleId IdType="pubmed">31154607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marić A, Kruljac I, Čerina V, Pećina HI, Šulentić P, Vrkljan M. Endocrinological outcomes of pure endoscopic transsphenoidal surgery: A croatian referral pituitary center experience. Croat Med J. 2012;53:224–233. doi: 10.3325/cmj.2012.53.224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3325/cmj.2012.53.224</ArticleId>
            <ArticleId IdType="pmc">PMC3368296</ArticleId>
            <ArticleId IdType="pubmed">22661135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kristof RA, Schramm J, Redel L, Neuloh G, Wichers M, Klingmu¨ller D. Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas. Acta Neurochir (Wien). 2002;144:555–561. doi: 10.1007/s00701-002-0938-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00701-002-0938-1</ArticleId>
            <ArticleId IdType="pubmed">12111488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan Z, Wang Y, Shou X, Su J, Lang L. Effect of transsphenoidal surgery and standard care on fertility related indicators of patients with prolactinomas during child-bearing period. Int J Clin Exp Med. 2015;8:21557–21564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4723950</ArticleId>
            <ArticleId IdType="pubmed">26885105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith TR, Hulou MM, Huang KT, Gokoglu A, Cote DJ, Woodmansee WW, et al.  Current indications for the surgical treatment of prolactinomas. J Clin Neurosci. 2015;22:1785–1791. doi: 10.1016/j.jocn.2015.06.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2015.06.001</ArticleId>
            <ArticleId IdType="pubmed">26277642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoo F, Chan C, Kuan E, Bergsneider M, Wang MB. Comparison of male and female prolactinoma patients requiring surgical intervention. J Neurol Surg. 2018;79:394–400. doi: 10.1055/s-0037-1615748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0037-1615748</ArticleId>
            <ArticleId IdType="pmc">PMC6043172</ArticleId>
            <ArticleId IdType="pubmed">30009121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho D, Liau W. Comparison of endonasal endoscopic surgery and sublabial microsurgery for prolactinomas. Surg Neurol. 2002;58:371–376. doi: 10.1016/S0090-3019(02)00892-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0090-3019(02)00892-3</ArticleId>
            <ArticleId IdType="pubmed">12517610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W, Zahr RS, McCartney S, Cetas JS, Dogan A, Fleseriu M. Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study. Pituitary. 2018;21:454–462. doi: 10.1007/s11102-018-0898-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-018-0898-y</ArticleId>
            <ArticleId IdType="pubmed">29936681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Jin D, Lian W, Xing B, Feng M, Liu X, et al.  Clinical characteristics and surgical outcome of prolactinoma in patients under 14 years old. Medicine (Baltimore). 2019;98:e14380. doi: 10.1097/MD.0000000000014380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000014380</ArticleId>
            <ArticleId IdType="pmc">PMC6380812</ArticleId>
            <ArticleId IdType="pubmed">30732174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santoro A, Minniti G, Ruggeri A, Esposito V, Jaffrain-Rea M-L, Delfini R. Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrinologic follow-up results. Surg Neurol. 2007;68:513–518. doi: 10.1016/j.surneu.2007.05.057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.surneu.2007.05.057</ArticleId>
            <ArticleId IdType="pubmed">17961741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bevan JS, Adams CBT, Burke CW, Morton KE, Molyneux AJ, Moore RA, et al.  Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy. Clin Endocrinol (Oxf). 1987;26:541–556. doi: 10.1111/j.1365-2265.1987.tb00809.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.1987.tb00809.x</ArticleId>
            <ArticleId IdType="pubmed">3665118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nelson PB, Goodman M, Maroon JC, Martinez AJ, Moossy J, Robinson AG. Factors in predicting outcome from operation in patients with prolactin-secreting pituitary adenomas. Neurosurgery. 1983;13:634–641. doi: 10.1227/00006123-198312000-00002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1227/00006123-198312000-00002</ArticleId>
            <ArticleId IdType="pubmed">6361599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Micko A, Vila G, Höftberger R, Knosp E, Wolfsberger S. Endoscopic transsphenoidal surgery of microprolactinomas: A reappraisal of cure rate based on radiological criteria. Neurosurgery. 2018;0:1–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30169711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jho H. Endoscopic transsphenoidal surgery. J Neurooncol. 2001;54:187–195. doi: 10.1023/A:1012969719503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1012969719503</ArticleId>
            <ArticleId IdType="pubmed">11761435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gondim JA, Schops M, de Almeida JPC, Albuquerque LAF, Gomes E, Tn F, et al.  Endoscopic endonasal transsphenoidal surgery: surgical results of 228 pituitary adenomas treated in a pituitary center. Pituitary. 2010;13:68–77. doi: 10.1007/s11102-009-0195-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-009-0195-x</ArticleId>
            <ArticleId IdType="pubmed">19697135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jho HD, Carrau RL. Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. J Neurosurg. 1997;87:44–51. doi: 10.3171/jns.1997.87.1.0044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/jns.1997.87.1.0044</ArticleId>
            <ArticleId IdType="pubmed">9202264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F, Zhou T, Wei S, Zhang J, Hou Y, Sun G. Endoscopic endonasal transsphenoidal surgery of 1,166 pituitary adenomas. Surg Endosc. 2015;29:1270–1280. doi: 10.1007/s00464-014-3815-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00464-014-3815-0</ArticleId>
            <ArticleId IdType="pmc">PMC4422857</ArticleId>
            <ArticleId IdType="pubmed">25270611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hofstetter CP, Shin BJ, Mubita L, Huang C, Anand VK, Boockvar JA, et al.  Endoscopic endonasal transsphenoidal surgery for functional pituitary adenomas. Neurosurg Focus. 2011;30:E10–E1E. doi: 10.3171/2011.1.FOCUS10317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2011.1.FOCUS10317</ArticleId>
            <ArticleId IdType="pubmed">21456921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yano S, Kawano T, Kudo M, Makino K, Nakamura H, Kai Y, et al.  Endoscopic endonasal transsphenoidal approach through the bilateral nostrils for pituitary adenomas. Neurol Med Chir (Tokyo). 2009;49:1–7. doi: 10.2176/nmc.49.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2176/nmc.49.1</ArticleId>
            <ArticleId IdType="pubmed">19168995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paluzzi A, Fernandez-Miranda JC, Stefko ST, Challinor S, Snyderman CH, Gardner PA. Endoscopic endonasal approach for pituitary adenomas: a series of 555 patients. Pituitary. 2014;17:307–319. doi: 10.1007/s11102-013-0502-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-013-0502-4</ArticleId>
            <ArticleId IdType="pubmed">23907570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Webster J, Page MD, Bevan JS, Richards SH, Douglas-Jonest AG, Scanlon MF. Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests. Clin Eadocrinol. 1992;36:35–44. doi: 10.1111/j.1365-2265.1992.tb02900.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.1992.tb02900.x</ArticleId>
            <ArticleId IdType="pubmed">1559298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodman EF, Molitch ME, Post KD, Biller BJ, Reichlin S. Long-term follow-up of transsphenoidal selective adenomectomy for prolactinoma. J Am Med Assoc. 1984;252:921–924. doi: 10.1001/jama.1984.03350070039020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.1984.03350070039020</ArticleId>
            <ArticleId IdType="pubmed">6431121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciccarelli E, Ghigo E, Miola C, Gandini G, Muller EE, Camanni F. Long-term follow-up of ‘cured’ prolactinoma patients after successful adenomectomy. Clin Endocrinol (Oxf). 1990;32:583–592. doi: 10.1111/j.1365-2265.1990.tb00901.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.1990.tb00901.x</ArticleId>
            <ArticleId IdType="pubmed">2114241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlechte JA, Sherman BM, Chapler FK, Van Gilder J. Long term follow-up of women with surgically treated prolactin- secreting pituitary tumors. J Clin Endocrinol Metab. 1986;62:1296–1301. doi: 10.1210/jcem-62-6-1296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem-62-6-1296</ArticleId>
            <ArticleId IdType="pubmed">3084539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakagawa H, Iwatsuki K, Yamada M, Hagiwara Y, Moriuchi S, Kadota T. Latent prolactinoma on MRI-selective venous sampling and trans-sphenoidal microsurgical treatment. Neurol Res. 2001;23:691–696. doi: 10.1179/016164101101199199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1179/016164101101199199</ArticleId>
            <ArticleId IdType="pubmed">11680507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parl FF, Cruz VE, Cobb CA, Bradley CA, Aleshire SL. Late recurrence of surgically removed prolactinomas. Cancer. 1986;57:2422–2426. doi: 10.1002/1097-0142(19860615)57:12&lt;2422::AID-CNCR2820571229&gt;3.0.CO;2-B.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1097-0142(19860615)57:12&lt;2422::AID-CNCR2820571229&gt;3.0.CO;2-B</ArticleId>
            <ArticleId IdType="pubmed">3697940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sata A, Hizuka N, Kawamata T, Hori T, Takano K. Hyponatremia after transsphenoidal surgery for hypothalamo-pituitary tumors. Neuroendocrinology. 2006;83:117–122. doi: 10.1159/000094725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000094725</ArticleId>
            <ArticleId IdType="pubmed">16864995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arafah BUM, Brodkey JS, Pearson OH. Gradual recovery of lactotroph responsiveness following surgical removal of prolactinomas. Metabolism. 1986;35:905–912. doi: 10.1016/0026-0495(86)90052-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0026-0495(86)90052-1</ArticleId>
            <ArticleId IdType="pubmed">3093797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirohata T, Uozumi T, Mukada K, Arita K, Kurisu K, Yano T, et al.  Influence of pregnancy on the serum prolactin level following prolactinoma surgery. Acta Endocrinol (Copenh). 1991;125:259–267. doi: 10.1530/acta.0.1250259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/acta.0.1250259</ArticleId>
            <ArticleId IdType="pubmed">1950339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massoud F, Serri O, Hardy J, Somma M, Beauregard H. Transsphenoidal adenomectomy for microprolactinomas 10 to 20 years of follow-up. Surg Neurol. 1996;45:341–346. doi: 10.1016/0090-3019(95)00430-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0090-3019(95)00430-0</ArticleId>
            <ArticleId IdType="pubmed">8607082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fraioli MF, Umana G, Pagano A, Fraioli B, Lunardi P. Prolactin secreting pituitary microadenoma: Results of transsphenoidal surgery after medical therapy with dopamine agonist. J Craniofac Surg. 2017;28:992–994. doi: 10.1097/SCS.0000000000003663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/SCS.0000000000003663</ArticleId>
            <ArticleId IdType="pubmed">28277481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, et al.  Prognostic factors in prolactin pituitary tumors: Clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab. 2010;95:1708–1716. doi: 10.1210/jc.2009-1191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2009-1191</ArticleId>
            <ArticleId IdType="pubmed">20164287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fahlbusch R, Buchfelder M. Present status of neurosurgery in the treatment of prolactinomas. Neurosurg Rev. 1985;8:195–205. doi: 10.1007/BF01815444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01815444</ArticleId>
            <ArticleId IdType="pubmed">2863782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sughrue ME, Chang EF, Tyrell JB, Kunwar S, Wilson CB, Jr, LSB. Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection. Pituitary. 2009;12:158–164. doi: 10.1007/s11102-008-0135-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-008-0135-1</ArticleId>
            <ArticleId IdType="pubmed">18651225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babey M, Sahli R, Vajtai I, Andres RH, Seiler RW. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary. 2011;14:222–230. doi: 10.1007/s11102-010-0283-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-010-0283-y</ArticleId>
            <ArticleId IdType="pmc">PMC3146980</ArticleId>
            <ArticleId IdType="pubmed">21170594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pelkonen R, Grahne B, Hirvonen E, Karonen S-L, Salmi J, Tikkanen M, et al.  Pituitary function in prolactinoma. effect of surgery and postoperative bromocriptine therapy. Clin Eadocrinol. 1980;14:335–348. doi: 10.1111/j.1365-2265.1981.tb00618.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.1981.tb00618.x</ArticleId>
            <ArticleId IdType="pubmed">7261416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Primeau V, Raftopoulos C, Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol. 2012;166:779–786. doi: 10.1530/EJE-11-1000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-11-1000</ArticleId>
            <ArticleId IdType="pubmed">22301915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, et al.  Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol. 2008;158:11–18. doi: 10.1530/EJE-07-0248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-07-0248</ArticleId>
            <ArticleId IdType="pubmed">18166812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawamata T, Iseki H, Ishizaki R, Hori T. Minimally invasive endoscope-assisted endonasal trans-sphenoidal microsurgery for pituitary tumors: Experience with 215 cases comparing with sublabial trans-sphenoidal approach. Neurol Res. 2002;24:259–265. doi: 10.1179/016164102101199882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1179/016164102101199882</ArticleId>
            <ArticleId IdType="pubmed">11958419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfsberger S, Czech T, Vierhapper H, Benavente R, Knosp E. Microprolactinomas in males treated by transsphenoidal surgery. Acta Neurochir (Wien). 2003;145:935–941. doi: 10.1007/s00701-003-0134-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00701-003-0134-y</ArticleId>
            <ArticleId IdType="pubmed">14628197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mamelak AN, Carmichael J, Bonert VH, Cooper O, Melmed S. Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases. Pituitary. 2013;16:393–401. doi: 10.1007/s11102-012-0437-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-012-0437-1</ArticleId>
            <ArticleId IdType="pubmed">23011322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han Y, Chen D, Zhang C, Pan M, Yang X-P, Wu Y-G. Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery. Medicine (Baltimore). 2018;97:e13198. doi: 10.1097/MD.0000000000013198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000013198</ArticleId>
            <ArticleId IdType="pmc">PMC6250442</ArticleId>
            <ArticleId IdType="pubmed">30407358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortini P, Losa M, Barzaghi R, Boari N, Giovanelli M. Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery. 2005;56:1222–1233. doi: 10.1227/01.NEU.0000159647.64275.9D.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1227/01.NEU.0000159647.64275.9D</ArticleId>
            <ArticleId IdType="pubmed">15918938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koizumi K, Aono T, Koike K, Kurachi K. Restoration of LH pulsatility in patients with prolactinomas after trans-sphenoidal surgery. Acta Endocrinol (Copenh). 1984;107:433–438. doi: 10.1530/acta.0.1070433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/acta.0.1070433</ArticleId>
            <ArticleId IdType="pubmed">6440387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serri O, Rasio E, Beauregard H, Hardy J, Somma M. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med. 1983;309:280–283. doi: 10.1056/NEJM198308043090505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM198308043090505</ArticleId>
            <ArticleId IdType="pubmed">6866052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akin S, Isikay I, Soylemezoglu F, Yucel T, Gurlek A, Berker M. Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases. Acta Neurochir (Wien). 2016;158:933–942. doi: 10.1007/s00701-016-2762-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00701-016-2762-z</ArticleId>
            <ArticleId IdType="pubmed">26970763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dehdashti AR, Ganna A, Karabatsou K, Gentili F. Pure endoscopic endonasal approach for pituitary adenomas early surgical results in 200 patients and comparison with previous microsurgical series. Neurosurgery. 2007;62:1006–1017. doi: 10.1227/01.neu.0000325862.83961.12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1227/01.neu.0000325862.83961.12</ArticleId>
            <ArticleId IdType="pubmed">18580798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woosley RE, King JS, Talbert L. Prolactin-secreting pituitary adenomas: neurosurgical management of 37 patients. Fertil Steril. 1982;37:54. doi: 10.1016/S0015-0282(16)45977-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0015-0282(16)45977-7</ArticleId>
            <ArticleId IdType="pubmed">7199482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maira G, Anile C, De Marinis L. Prolactin-secreting adenomas: surgical results and long-term follow-up. Neurosurgery. 1989;24:736–743. doi: 10.1227/00006123-198905000-00013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1227/00006123-198905000-00013</ArticleId>
            <ArticleId IdType="pubmed">2716983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Yao Y, Xing B, Lian W, Deng K, Feng M, et al.  Prolactinomas in children under 14. Clinical presentation and long-term follow-up. Childs Nerv Syst. 2015;31:909–916. doi: 10.1007/s00381-015-2679-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00381-015-2679-5</ArticleId>
            <ArticleId IdType="pubmed">25771923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faria JMA, Tindall GT. Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. J Neurosurg. 1982;56:33. doi: 10.3171/jns.1982.56.1.0033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/jns.1982.56.1.0033</ArticleId>
            <ArticleId IdType="pubmed">7198681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esposito V, Santoro A, Minniti G, Salvati M, Innocenzi G, Lanzetta G, et al.  Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: outcome analysis in a series of 125 patients. Neurol Sci. 2004;25:251–256. doi: 10.1007/s10072-004-0351-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-004-0351-z</ArticleId>
            <ArticleId IdType="pubmed">15624082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soule SG, Farhi J, Conway GS, Jacobs HS, Powell M. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy. Clin Endocrinol (Oxf). 1996;44:711–716. doi: 10.1046/j.1365-2265.1996.738559.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2265.1996.738559.x</ArticleId>
            <ArticleId IdType="pubmed">8759184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frank G, Pasquini E, Farneti G, Mazzatenta D, Sciarretta V, Grasso V, et al.  The endoscopic versus the traditional approach in pituitary surgery. Neuroendocrinology. 2006;83:240–248. doi: 10.1159/000095534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000095534</ArticleId>
            <ArticleId IdType="pubmed">17047389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: Early results and long-term outcome. J Clin Endocrinol Metab. 2002;87:3180–3186. doi: 10.1210/jcem.87.7.8645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.87.7.8645</ArticleId>
            <ArticleId IdType="pubmed">12107221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charpentier G, de Plunkett T, Jedynak P, Peillon F, Le Gentil P, Racadot J, et al.  Surgical treatment of prolactinomas short- and long-term results, prognostic factors. Horm Res Paediatr. 1985;22:222–227. doi: 10.1159/000180098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000180098</ArticleId>
            <ArticleId IdType="pubmed">4054842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song Y, Chen M, Lian W, Xing B, Yao Y, Feng M, et al.  Surgical treatment for male prolactinoma A retrospective study of 184 cases. Medicine (Baltimore). 2017;96:e5833. doi: 10.1097/MD.0000000000005833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000005833</ArticleId>
            <ArticleId IdType="pmc">PMC5266175</ArticleId>
            <ArticleId IdType="pubmed">28079813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donegan D, Atkinson JLD, Jentoft M, Natt N, Nippoldt TB, Erickson B, et al.  Surgical outcomes of prolactinomas in recent era: Results of a heterogenous group. Endocr Pract. 2017;23:37–45. doi: 10.4158/EP161446.OR.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4158/EP161446.OR</ArticleId>
            <ArticleId IdType="pubmed">27682355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamilton DK, Vance ML, Boulos PT, Laws ER. Surgical outcomes in hyporesponsive prolactinomas: Analysis of patients with resistance or intolerance to dopamine agonists. Pituitary. 2005;8:53–60. doi: 10.1007/s11102-005-5086-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11102-005-5086-1</ArticleId>
            <ArticleId IdType="pubmed">16411069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qu X, Wang M, Wang G, Han T, Mou C, Han L, et al.  Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. Eur J Endocrinol. 2011;164:499–504. doi: 10.1530/EJE-10-0961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-10-0961</ArticleId>
            <ArticleId IdType="pubmed">21252173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saitoh Y, Mori S, Arita N, Nagatani M, Hayakawa T, Koizumi K, et al.  Treatment of prolactinoma based on the results of transsphenoidal operations. Surg Neurol. 1986;26:338–344. doi: 10.1016/0090-3019(86)90133-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0090-3019(86)90133-3</ArticleId>
            <ArticleId IdType="pubmed">3750191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomson JA, Teasdale GM, Gordon D, Mccruden DC, Davies DL. Treatment of presumed prolactinoma by transsphenoidal operation: early and late results. Br Med J. 1985;291:1550–1553. doi: 10.1136/bmj.291.6508.1550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.291.6508.1550</ArticleId>
            <ArticleId IdType="pmc">PMC1418156</ArticleId>
            <ArticleId IdType="pubmed">3933747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamasauskas A, Sinkunas K, Bunevicius A, Radziunas A, Skiriute D, Deltuva VP. Transsphenoidal surgery for microprolactinomas in women: results and prognosis. Acta Neurochir (Wien). 2012;154:1889–1893. doi: 10.1007/s00701-012-1450-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00701-012-1450-x</ArticleId>
            <ArticleId IdType="pubmed">22855071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner HE, Adams CB, Wass JA. Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists? Eur J Endocrinol. 1999;140:43–47. doi: 10.1530/eje.0.1400043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/eje.0.1400043</ArticleId>
            <ArticleId IdType="pubmed">10037250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikeda H, Watanabe K, Tominaga T, Yoshimoto T. Transsphenoidal microsurgical results of female patients with prolactinomas. Clin Neurol Neurosurg. 2013;115:1621–1625. doi: 10.1016/j.clineuro.2013.02.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clineuro.2013.02.016</ArticleId>
            <ArticleId IdType="pubmed">23498159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi N, Ji L, Zhang Q, Zhang S, Liu X, Shou X, et al. Long-term follow-up of female prolactinoma patients at childbearing age after transsphenoidal surgery. Endocrine. 2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29934876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al.  Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273–288. doi: 10.1210/jc.2010-1692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2010-1692</ArticleId>
            <ArticleId IdType="pubmed">21296991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiter D, Primeau V. 2012 update in the treatment of prolactinomas. Annales d'Endocrinologie. 2012;73:90–98. doi: 10.1016/j.ando.2012.03.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ando.2012.03.024</ArticleId>
            <ArticleId IdType="pubmed">22503806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cappabianca P, Cavallo LM, Solari D. Transsphenoidal surgery: A journey of 50 years. World Neurosurg. 2013;79:253–254. doi: 10.1016/j.wneu.2012.10.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.wneu.2012.10.035</ArticleId>
            <ArticleId IdType="pubmed">23103262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014;170:R213–R227. doi: 10.1530/EJE-14-0013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-14-0013</ArticleId>
            <ArticleId IdType="pubmed">24536090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan L, Yan H, Huang M, Zhang Y, Gu F. An economic analysis of bromocriptine versus trans-sphenoidal surgery for the treatment of prolactinoma. J Craniofac Surg. 2017;28:1046–1051. doi: 10.1097/SCS.0000000000003456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/SCS.0000000000003456</ArticleId>
            <ArticleId IdType="pubmed">28145933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jingran Z, Qi Y, Yuhui Z. Cost-effectiveness analysis of two therapeutic methods for prolactinoma. Chin J Obstet Gynecol. 2008;43:257–261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18843964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zygourakis CC, Imber BS, Chen R, Han SJ, Blevins L, Molinaro A, et al.  Cost-effectiveness analysis of surgical versus medical treatment of prolactinomas. J Neurol Surg. 2017;78:125–131. doi: 10.1055/s-0037-1608635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0037-1608635</ArticleId>
            <ArticleId IdType="pmc">PMC5357228</ArticleId>
            <ArticleId IdType="pubmed">28321375</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
